Global Micro Invasive Glaucoma Surgery (MIGS) Devices Market Size By Type (MIGS Stents, MIGS Shunts), By Application (Hospital, Ophthalmology Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Micro Invasive Glaucoma Surgery (MIGS) Devices Market was valued at USD 1.3 billion in 2023 and is projected to reach USD 4.2 billion by 2031, growing at a CAGR of 15.9% during the forecast period from 2023 to 2031. The growth is fueled by the rising prevalence of glaucoma, the aging population worldwide, and the increasing demand for minimally invasive surgical techniques that offer faster recovery and reduced risk of complications. MIGS devices have become a transformative solution in ophthalmology, offering safer alternatives to traditional glaucoma surgeries.

Drivers:

Rising Prevalence of Glaucoma:

Glaucoma remains a leading cause of irreversible blindness globally. According to the World Health Organization, over 76 million people were affected by glaucoma in 2020, with projections expected to surpass 100 million by 2040. The rising incidence is propelling the demand for early, safe, and effective treatment interventions like MIGS.

Increasing Preference for Minimally Invasive Procedures:

MIGS procedures offer several advantages over traditional surgeries, such as smaller incisions, faster patient recovery, and fewer postoperative complications. This patient-centric approach is increasingly being preferred by ophthalmologists and patients alike.

Aging Global Population:

The risk of glaucoma increases significantly with age. As the global elderly population continues to rise, particularly in developed regions, the need for long-term glaucoma management solutions is expanding.

Restraints:

High Cost of MIGS Devices:

Although effective, the cost of MIGS devices and associated surgical procedures is relatively high. This limits accessibility, particularly in low- and middle-income countries, posing a challenge to widespread adoption.

Lack of Skilled Ophthalmic Surgeons:

The execution of MIGS procedures requires specialized training. A shortage of trained ophthalmic surgeons proficient in these new technologies may hinder growth in certain regions.

Opportunity:

Technological Advancements and Product Innovation:

Continuous innovation in device design, such as the development of biodegradable implants and drug-eluting stents, offers significant growth potential. New entrants and established players are investing heavily in R&D to expand their product portfolios and improve surgical outcomes.

Expansion in Emerging Economies:

Countries in Asia-Pacific and Latin America are experiencing growing healthcare investments and improved access to eye care, presenting vast opportunities for MIGS device manufacturers to tap into underserved glaucoma markets.

Market by System Type Insights:

The stent-based devices segment accounted for the largest market share in 2023. Devices such as iStent and Hydrus Microstent have gained widespread acceptance due to their proven efficacy in lowering intraocular pressure (IOP) with minimal trauma. The segment is expected to maintain dominance, driven by continuous improvements in stent design and ease of implantation.

Conversely, shunt-based devices are anticipated to witness the fastest growth rate during the forecast period. These devices offer promising results for patients with moderate to severe glaucoma where more aggressive IOP management is necessary.

Market by End-use Insights:

The hospitals segment emerged as the dominant end-user in 2023, supported by advanced surgical infrastructure and the presence of experienced ophthalmologists. Hospitals continue to be the primary centers for MIGS procedures, offering comprehensive pre- and post-operative care.

Meanwhile, ambulatory surgical centers (ASCs) are expected to grow rapidly, driven by a shift toward outpatient glaucoma surgeries that offer lower costs and shorter patient wait times.

Market by Regional Insights:

North America held the largest market share in 2023, attributed to robust healthcare infrastructure, early adoption of innovative surgical techniques, and favorable reimbursement policies. The U.S. market, in particular, leads in terms of procedural volume and device approvals.

The Asia-Pacific region is poised for the highest growth, spurred by a large patient base, increasing awareness of glaucoma treatment, and a rising number of ophthalmic clinics equipped to perform MIGS procedures.

Competitive Scenario:

Prominent players in the Global MIGS Devices Market include Glaukos Corporation, Alcon Inc., Ivantis Inc. (acquired by Alcon), Santen Pharmaceutical Co., Ltd., AbbVie Inc., and MicroOptx Inc. These companies are focusing on new product launches, clinical trials, and global expansion strategies. For instance:

In 2023, Alcon received FDA approval for its Hydrus Microstent for expanded indications in mild-to-moderate glaucoma.

Glaukos Corporation launched the next-generation iStent Infinite system in 2024, offering enhanced performance and longer durability.

Santen collaborated with a leading university hospital in Japan in 2022 to initiate clinical studies on novel drug-eluting MIGS devices.

Scope of Work – Global Micro Invasive Glaucoma Surgery (MIGS) Devices Market

Report Metric Details

Market Size (2023) USD 1.3 Billion

Projected Market Size (2031) USD 4.2 Billion

CAGR (2023-2031) 15.9%

Key Segments by System Type Stent-based Devices, Shunt-based Devices

Key Segments by End-Use Hospitals, Ambulatory Surgical Centers

Leading Region North America

Key Players Glaukos, Alcon, Santen, AbbVie, MicroOptx

Growth Drivers Aging Population, Demand for Minimally Invasive Surgery, Technological Innovation

Opportunities Product Innovation, Expansion in Emerging Markets

Key Market Developments:

2023: Alcon received FDA clearance for the expanded use of its Hydrus Microstent.

2024: Glaukos launched its iStent Infinite system, further enhancing its MIGS portfolio.

2022: Santen announced a strategic R&D partnership for drug-eluting MIGS implants to enhance post-operative glaucoma management.

FAQs:

What is the current market size of the Global Micro Invasive Glaucoma Surgery (MIGS) Devices Market?

The market was valued at USD 1.3 billion in 2023.

What is the major growth driver of the Global Micro Invasive Glaucoma Surgery (MIGS) Devices Market?

The increasing demand for minimally invasive procedures and the rising global prevalence of glaucoma.

Which is the largest region during the forecast period in the Global Micro Invasive Glaucoma Surgery (MIGS) Devices Market?

North America is projected to remain the dominant region.

Which segment accounted for the largest market share in Global Micro Invasive Glaucoma Surgery (MIGS) Devices Market?

The stent-based devices segment held the largest share in 2023.

Who are the key market players in the Global Micro Invasive Glaucoma Surgery (MIGS) Devices Market?

Key players include Glaukos Corporation, Alcon Inc., Santen Pharmaceutical, AbbVie Inc., and MicroOptx Inc.